SCHEMBL3228262

SCHEMBL3228262

CCCC1(C)C(=O)C(C)(C)Nc2c1cc(-c1cccc3nccn13)c1c2CCC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 10/20 0.80
▸ PGR P06401 2/20 0.48
▸ CDK8 P49336 2/20 0.39
▸ ROCK1 Q13464 2/20 0.39
▸ FLT1 P17948 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ LIMK1 P53667 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ MAP4K1 Q92918 1/20 0.33
▸ CHEK1 O14757 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ PRKACA P17612 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ MAP2K1 Q02750 1/20 0.32
▸ ACVR1 Q04771 1/20 0.32
▸ MAP4K2 Q12851 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32
▸ AURKB Q96GD4 1/20 0.32
▸ DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227200 0.95 NR3C1 (0.77) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL4253956 0.93 NR3C1 (0.79) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3234751 0.91 NR3C1 (0.76) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3231046 0.90 NR3C1 (0.75) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3228486 0.89 NR3C1 (1.00) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3235149 0.88 NR3C1 (0.74) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3232747 0.87 NR3C1 (0.73) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3232751 0.87 NR3C1 (0.73) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3222388 0.87 NR3C1 (0.73) NR3C1PGRCDK8ROCK1FLT1
SCHEMBL3234015 0.87 NR3C1 (0.73) NR3C1PGRCDK8ROCK1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2116538-B1 CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES MITSUBISHI TANABE PHARMA CORP (JP) 2013-03-27 — — EP disclosed
US-8367695-B2 Condensed tetrahydroquinoline derivative and use thereof for medical purposes MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-02-05 — — US disclosed
US-20100063055-A1 CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 — — US disclosed
EP-2116538-A1 CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Mitsubishi Tanabe Pharma Corporation (JP) 2009-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063055-A1 CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES NR3C2, MC2R, NR5A1 NR3C1 4/4885PGR 11/4885CDK8 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback